Skip to content
sellWeak

Stephen Ray Mitchell sold $32k of VNDA

director at Vanda Pharmaceuticals Inc.. 7,000 shares at an average of $4.59, traded Jun 13, 2025, filed Jun 16, 2025.

Warning score
20
Value
$32k
7,000 shares
Holdings after
97,082
-7% from before
From 52-week low
+15%
low $3.92, close $4.51
From 52-week high
-17%
high $5.46, as of Jun 13, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $32k at market
    +5
  • Share of holdings sold
    Sold 6.7% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +5.0%, 3m -4.4%, 6m +44.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VNDAOct 12, 2026 · close 4.54
Since filing Jun 16, 2025: -0.9%SPY +31.2% · excess -32.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-25-087025, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 13, 2025SOpen-market sale
Common Stock
-7,000$4.59$32k97,082Jun 16, 2025

Related signals

Other insiders at Vanda Pharmaceuticals Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
VNDAsell 6
Vanda Pharmaceuticals Inc.
Gunther Birznieks
SVP, Business Development
$351k
42,431 shares
-8%
52Moderate
VNDAsell 6
Vanda Pharmaceuticals Inc.
Kevin Patrick Moran
SVP, CFO & Treasurer
$351k
42,442 shares
-9%
65Notable
VNDAsell 6
Vanda Pharmaceuticals Inc.
Mihael Hristos Polymeropoulos
President and CEO
$1.3M
156,235 shares
-5%
50Moderate
VNDAsell 6
Vanda Pharmaceuticals Inc.
Timothy Williams
SVP & General Counsel
$351k
42,434 shares
-10%
43Moderate
VNDAsell 6
Vanda Pharmaceuticals Inc.
Joakim Wijkstrom
SVP, Chief Marketing Officer
$255k
30,800 shares
-8%
48Moderate
VNDAsell 6
Vanda Pharmaceuticals Inc.
Tage Honore
director
$241k
30,000 shares
-24%
45Moderate
VNDAbuy
Vanda Pharmaceuticals Inc.
Mihael Hristos Polymeropoulos
President and CEO
$42k
10,000 shares
+0%
35Weak
VNDAbuy
Vanda Pharmaceuticals Inc.
Mihael Hristos Polymeropoulos
President and CEO
$44k
10,000 shares
+0%
43Moderate
VNDAbuy
Vanda Pharmaceuticals Inc.
Mihael Hristos Polymeropoulos
President and CEO
$84k
20,000 shares
+1%
25Weak
VNDAsell
Vanda Pharmaceuticals Inc.
Stephen Ray Mitchell
director
$26k
5,000 shares
-10%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Stephen Ray Mitchell sold $32k of VNDA | InsiderTell